Angioedema - 90 Studies Found

Completed : Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
: Angioedema
: 2009-12-18
: Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin subcutaneous dose of 3
Completed : C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
: Angioedema
: 2005-07-29
: Drug: C1 inhibitor concentrate (C1-esteraseremmer-N) every 5-7 days
Not yet recruiting : Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
: Idiopathic Angioedema
: 2016-11-15
:
  • Drug: Omalizumab Omalizumab 30
Completed : Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
: Hereditary Angioedema
: 2007-02-07
: Drug: C1 esterase inhibitor [human] (C1INH-nf)
Completed : AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study
: Angioedema
: 2010-06-29
:
  • Drug: Icatibant (subcutaneous) and plazebo (intravenous)
Completed : Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
: Hereditary Angioedema
: 2007-02-21
: Biological: C1 esterase inhibitor [human] (C1INH-nf)
Completed : Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
: Hereditary Angioedema
: 2007-04-17
: Biological: C1 esterase inhibitor [human] (C1INH-nf)
Completed : Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
: Angioedema
: 2004-11-26
:
  • Drug: Icatibant 30 mg (3mL) su
Completed : Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
: Hereditary Angioedema
: 2015-10-23
:
  • Drug: DX-2930 - 300mg/2wk 300

Active, not recruiting : Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
: Hereditary Angioedema
: 2016-04-08
:
  • Drug: DX-2930 Rollover subject
Next >>>